P2B-001 combines a dopamine agonist (pramipexole) and a MAO-B inhibitor (rasagiline) in a small molecule formulation. It targets motor impairment by both stimulating dopamine receptors and preventing dopamine breakdown, thus enhancing dopamine availability.
Discover our Products
Science-based and high-quality devices
